Menu

Infographic: How to Build a Synthetic Sensor

Scientists designed a genetic sensor-and-readout system, based on detecting a transcription factor, that performs a custom cellular activity.

Nov 30, 2016
Ruth Williams

© LUCY READING-IKKANDA

Synthetic Circuit

In this example of a typical transducer, the genetic construct (top) includes an amplifier response element and a carefully positioned transcription factor response element upstream of a promoter that drives expression of a fusion gene (the combined effector of choice and an amplifier). In the presence of a specific endogenous transcription factor, which binds to the transcription factor response element, the fusion gene is expressed. Cleavage of the fusion protein releases the amplifier, which together with the transcription factor drives much stronger expression. The system is like a positive feedback loop, but neither the transcription factor nor the amplifier alone can drive strong expression—they need each other.

Read the full story.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.